104344-23-2 Manufacturer CAS NO.104344-23-2

Synonyms:1-[4-[[2-(1-METHYLETHOXY)ETHOXY]METHYL]PHENOXY]-3-[(1-METHYLETHYL)AMINO]-2-PROPANOL

(+/-)-1-[4-[[(2-(1-METHYLETHOXY)ETHOXY)METHYL]PHENOXY]-3-[(1-METHYLETHYL)AMINO]-2-PROPANOL] HEMIFUMARATE
BISOPROLOL
(+/-)-BISOPROLOL HEMIFUMARATE
BISOPROLOL HEMIFUMARATE
CONCOR
DETENSIEL
EMCOR
EURADIAL
ISOTEN
MONOCOR
SOPROL
ZEBETA
(+-)-1-(p-((2-isopropoxyethoxy)methyl)phenoxy)-3-isopropylamino-2-propanolh
(+-)-mino)(e)-2-butenedioate(2:1)(salt)
2-propanol,1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)a
emd33512
emifumarate
1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol, Concor, Detensiel, Emcor, Euradial, Isoten, Monocor, Soprol, Zebeta,
2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-, (+-)-, (E)-2-butenedioate (2:1) (salt) (8CI)

Pharmacological effects :

Bisoprolol fumarate is selective beta 1- adrenergic receptor blockers. No internalquasi stable effect of sympathetic activity and membrane. Experimental animals of different models show it with beta 1- receptor affinity than beta receptor 2- 11 ~ 34 times, the selectivity to the beta 1 receptor is a similar drug atenolol (Atenolol) 4 times. This product is the role of a long time (more than 24 hours), continuous administration of symptoms and had not tolerance control, side effects on therespiratory effects of minimal, no fat catabolism. On bronchial beta 2 receptor alsoblock to some extent, but only at a high dose may occur, generally no clinical significance.

indications:

The treatment of essential hypertension. As first-line antihypertensive drug, used alone or with diuretics and vasodilators combined application.

Angina pectoris and myocardial infarction.

Arrhythmia, such as rapid supraventricular arrhythmia, ventricular prematurecontraction.

In recent years, bisoprolol fumarate also tried for the treatment of heart failure. On the previously received ACE inhibitors, diuretics and cardiac glycosides drug treatment of ventricular systolic function (ejection fraction of 35% or less) with moderate to severe stable chronic congestive heart failure and effective.